Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (221-230 of 343) with videos related to

Pageof 35
Sort By:
Nature Reviews. Clinical Oncology|November 2, 2024
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemiaMichele D Stanchina, Skye Montoya, Alexey V Danilov, et al.
Blood Advances|August 22, 2020
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-upJorge J Castillo, Kirsten Meid, Catherine A Flynn, et al.
British Journal of Haematology|November 22, 2018
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinibMatthew P Cheng, Amanda E Kusztos, Joshua N Gustine, et al.
American Journal of Hematology|February 18, 2011
Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter studyJorge J Castillo, Brady E Beltran, Michele Bibas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)Steven P Treon, Kirsten Meid, Christina Tripsas, et al.
British Journal of Haematology|February 28, 2020
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemiaCristina Jiménez, Gloria G Chan, Lian Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström MacroglobulinemiaSteven P Treon, Kirsten Meid, Joshua Gustine, et al.
Blood|July 22, 2021
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndromeMarit Jalink, Sigbjørn Berentsen, Jorge J Castillo, et al.
Cancer|April 19, 2012
Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapyJorge J Castillo, Michael Furman, Brady E Beltrán, et al.
Blood Advances|September 21, 2020
Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemiaCristina Jiménez, Lian Xu, Nickolas Tsakmaklis, et al.
Pageof 35

Showing results (221-230 of 343) with videos related to

Sort By:
Pageof 35
Nature Reviews. Clinical Oncology|November 2, 2024
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemiaMichele D Stanchina, Skye Montoya, Alexey V Danilov, et al.
Blood Advances|August 22, 2020
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-upJorge J Castillo, Kirsten Meid, Catherine A Flynn, et al.
British Journal of Haematology|November 22, 2018
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinibMatthew P Cheng, Amanda E Kusztos, Joshua N Gustine, et al.
American Journal of Hematology|February 18, 2011
Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter studyJorge J Castillo, Brady E Beltran, Michele Bibas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)Steven P Treon, Kirsten Meid, Christina Tripsas, et al.
British Journal of Haematology|February 28, 2020
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemiaCristina Jiménez, Gloria G Chan, Lian Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström MacroglobulinemiaSteven P Treon, Kirsten Meid, Joshua Gustine, et al.
Blood|July 22, 2021
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndromeMarit Jalink, Sigbjørn Berentsen, Jorge J Castillo, et al.
Cancer|April 19, 2012
Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapyJorge J Castillo, Michael Furman, Brady E Beltrán, et al.
Blood Advances|September 21, 2020
Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemiaCristina Jiménez, Lian Xu, Nickolas Tsakmaklis, et al.
Pageof 35